A closer look at vancomycin, teicoplanin, and antimicrobial resistance.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of chemotherapy

• Publication date

  1997-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1179/JOC.1997.9.5.311PMID 9373787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THERAPEUTIC CONTROVERSIES

  2013cited by this paper
• Teicoplanin

  2012cited by this paper
• Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

  1997cited by this paper
• Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus

  1997cited by this paper
• Pharmacokinetics of a single dose of teicoplanin in burn patients.

  1996cited by this paper
• Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia

  1996cited by this paper
• Changes in susceptibilities to teicoplanin, vancomycin and other antibiotics among Staphylococcus aureus isolates in a tertiary-care University hospital.

  1996cited by this paper
• The comparative efficacy and safety of teicoplanin and vancomycin.

  1996cited by this paper
• Emergence of teicoplanin-resistant coagulase-negative staphylococci

  1996cited by this paper
• Nosocomial bacteremia due to vancomycin-resistantStaphylococcus epidermidis in four patients with cancer, neutropenia, and previous treatment with vancomycin

  1996cited by this paper
• Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.

  1996cited by this paper
• Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System.

  1996cited by this paper
• In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993.

  1996cited by this paper
• The comparative efficacy and safety of teicoplanin and vancomycin.

  1996cited by this paper
• Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus.

  1996cited by this paper
• Influence of inoculum, medium and serum on the in-vitro susceptibility of coagulase-negative staphylococci to teicoplanin and vancomycin.

  1996cited by this paper
• The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome

  1995cited by this paper
• Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

  1995cited by this paper
• Survival and therapy of burn patients at the threshold of the twenty-first century: a review.

  1995cited by this paper
• Right-sided endocarditis caused by Staphylococcus aureus in drug abusers

  1995cited by this paper
• Changes in the Serum Protein Binding of Vancomycin in Patients with Methicillin‐Resistant Staphylococcus aureus Infection: The Role of Serum α1‐Acid Glycoprotein Levels

  1995cited by this paper
• Susceptibility of nosocomial gram-positive cocci to teicoplanin and other antibiotics

  1995cited by this paper
• Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis

  1995cited by this paper
• In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis.

  1995cited by this paper
• Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections.

  1995cited by this paper
• Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.

  1995cited by this paper
• Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial.

  1995cited by this paper
• A critical review of the in-vitro activity of teicoplanin.

  1995cited by this paper
• Vancomycin-dependent Enterococci: a clinical and laboratory assessment.

  1995cited by this paper
• Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

  1995cited by this paper
• The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

  1995cited by this paper
• Sample Size for Therapeutic Equivalence Based on Confidence Interval

  1995cited by this paper
• Protein binding and serum bactericidal activities of vancomycin and teicoplanin

  1995cited by this paper
• Potential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant Staphylococcus aureus septicemia persisting under vancomycin therapy.

  1995cited by this paper
• Bacteremia due to vancomycin-dependent Enterococcus faecium.

  1995cited by this paper
• In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis

  1994cited by this paper
• Vancomycin toxicity. What is the evidence for dose dependency?

  1994cited by this paper
• Antibiotic treatment of burned patients: An Italian multicentre study

  1994cited by this paper
• Monitoring serum vancomycin levels: climbing the mountain because it is there?

  1994cited by this paper
• The continuing problem of 'hospital staphylococci': why?

  1994cited by this paper
• Vancomycine en administration continue chez le grand brûlé.

  1994cited by this paper
• Coagulase-negative staphylococci: pathogens associated with medical progress.

  1994cited by this paper
• In Vitro Evaluation of High‐Level, Gentamicin‐Resistant Enterococci Isolated from Bacteremic Patients

  1994cited by this paper
• Effect of Human Serum on Killing Activity of Vancomycin and Teicoplanin against Staphylococcus aureus

  1994cited by this paper
• Serum vancomycin concentrations: reappraisal of their clinical value.

  1994cited by this paper
• Failure of teicoplanin therapy in Staphylococcus aureus septicaemia.

  1994cited by this paper
• Update on clinical significance of coagulase-negative staphylococci

  1994cited by this paper
• Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

  1994cited by this paper
• A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer.

  1994cited by this paper
• Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program

  1994cited by this paper
• Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.

  1994cited by this paper
• Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci

  1994cited by this paper
• [Continuous administration of vancomycin in patients with severe burns].

  1994cited by this paper
• A critical review of the dosage of teicoplanin in Europe and the USA.

  1994cited by this paper
• [Methicillin resistant Staphylococcus aureus and glycopeptides (vancomycin, teicoplanin): in vitro selection of resistance].

  1994cited by this paper
• High rate of oxacillin-resistant Staphylococcus aureus isolates in an Italian University Hospital.

  1994cited by this paper
• Infections by ampicillin-resistant enterococci: a case-control study.

  1994cited by this paper
• Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients

  1994cited by this paper
• Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.

  1994cited by this paper
• [Antibacteriological activities of arbekacin and vancomycin against strains of MRSA].

  1994cited by this paper
• Epidemiology of infection in ICUs

  1994cited by this paper
• Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis

  1994cited by this paper
• Once daily antibiotic regimen in paediatric oncology.

  1994cited by this paper
• [Resistance spectrum of staphylococci at the Vienna general hospital (July to December 1991)].

  1994cited by this paper
• Safety and Efficacy of Teicoplanin for Bone and Joint Infections: Results of a Community-Based Trial

  1993cited by this paper
• Enterococcus faecium: in vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains.

  1993cited by this paper
• Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex

  1993cited by this paper
• Dosage recommendations for teicoplanin.

  1993cited by this paper
• Making sense of meta‐analysis

  1993cited by this paper
• Vancomycin resistance in gram-positive organisms

  1993cited by this paper
• Genetics and mechanisms of glycopeptide resistance in enterococci

  1993cited by this paper
• Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients

  1993cited by this paper
• [Vancomycin in meningitis caused by penicillin G resistant Streptococcus pneumoniae].

  1993cited by this paper
• Nosocomial infection in pediatric surgical patients: a study of 608 infants and children.

  1993cited by this paper
• Thrombocytopenia due to use of teicoplanin.

  1993cited by this paper
• Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial.

  1993cited by this paper
• Measuring the comparative efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon".

  1992cited by this paper
• The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents.

  1992cited by this paper
• Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

  1992cited by this paper
• [A comparative microbiological and pharmacokinetic activity of vancomycin and teicoplanin].

  1992cited by this paper
• Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group

  1992cited by this paper
• Pharmacokinetics of systemically administered antibiotics in patients with thermal injury.

  1992cited by this paper
• Efficacy of teicoplanin for enterococcal infections: 63 cases and review.

  1992cited by this paper
• Teicoplanin in the treatment of gram-positive bacteremia and endocarditis

  1992cited by this paper
• Bactericidal activity of antibiotics alone and in combination against Enterococcus faecalis in a pharmacodynamic model.

  1992cited by this paper
• Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity.

  1992cited by this paper
• Trimethoprim-Sulfamethoxazole Compared with Vancomycin for the Treatment of Staphylococcus aureus Infection

  1992cited by this paper
• Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.

  1992cited by this paper
• In vitro activity of teicoplanin compared with vancomycin against methicillin-resistant Staphylococcus aureus derived from cystic fibrosis sputum.

  1992cited by this paper
• Necessity of a loading dose when using vancomycin in critically ill patients.

  1992cited by this paper
• Bone and joint infections caused by multiply resistant Staphylococcus aureus in a neonatal intensive care unit.

  1992cited by this paper
• Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis

  1992cited by this paper
• Recurrent Staphylococcus aureus bacteremia

  1992cited by this paper
• In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

  1992cited by this paper
• Hospital-acquired Infection with Vancomycin-resistant Enterococcus faecium Transmitted by Electronic Thermometers

  1992cited by this paper
• Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility.

  1992cited by this paper
• Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia.

  1992cited by this paper
• A Cluster of Vancomycin-Resistant Enterococcus faecium in an Intensive Care Unit

  1992cited by this paper
• Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

  1991cited by this paper
• Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin

  1991cited by this paper

• Study of the Effectiveness of Precision Doses of Antibiotics in the Treatment of Induced Acute Bacterial Postoperative Endophthalmitis in an Experiment

  2019cites this paper
• Исследование эффективности прецизионных доз антибиотиков в лечении индуцированного острого бактериального послеоперационного эндофтальмита в эксперименте

  2019cites this paper
• Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis.

  2016cites this paper
• Randomized Study Infections: Prospective Multicenter Vancomycin in Severe Staphylococcal Continuous versus Intermittent Infusion of

  2014cites this paper
• Factors Affecting the Cost Effectiveness of Antibiotics

  2011cites this paper
• Teicoplanin versus vancomycin for proven or suspected infection.

  2010cites this paper
• Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versus Intermittent Infusion

  2009cites this paper
• Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline

  2009cites this paper
• Nephrotoxicity of Vancomycin and Teicoplanin Alone and in Combination with an Aminoglycoside

  2007cites this paper
• Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.

  2006cites this paper
• Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycin

  2006cites this paper
• Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.

  2003cites this paper
• Combinatorial glycosylation of glycopeptide antibiotics.

  2002cites this paper
• Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients.

  2002cites this paper
• Determination of bone and tissue concentrations of teicoplanin mixed with hydroxyapatite cement to repair cortical defects.

  2002cites this paper
• Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis.

  2001cites this paper
• Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study

  2001cites this paper
• Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients.

  2000influential citation
• Miscellaneous antibacterial drugs

  1999cites this paper
• DR. ZECKEL'S REPLY:

  1998cites this paper
• Aminoglycosides and vancomycin

  1998cites this paper
• Zeckel ML. A closer look at vancomycin, teicoplanin and antimicrobial resistance. J Chemother 1997; 9: 311-335.

  1998cites this paper
• Infective endocarditis and glycopeptides.

  1998cites this paper